Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Site–Specific (Targeted) Drug Delivery in Cancer Therapy

Bio/Technology volume 1, pages 869–878 (1983)Cite this article

Abstract

The current status of efforts to target cytotoxic agents to tumor cells using antitumor antibodies and particulate drug carriers such as liposomes and microspheres is reviewed. Emphasis is given to the role of anatomic and physiologic factors in determining the disposition, fate, and therapeutic efficacy of targeted drug delivery systems and to the importance of tumor cell heterogeneity as a major obstacle to effective cancer therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. DeVita, V.T. Jr., Hellman, S. and Rosenberg, S.A. (eds.) 1982. Cancer: Principles and Practice of Oncology. Lippincott, Philadelphia.

    Google Scholar 

  2. Poste, G. and Fidler, I.J. 1980. The pathogenesis of cancer metastasis. Nature 283: 139–146.

    Article  CAS  Google Scholar 

  3. Poste, G. 1982. Experimental systems for analysis of the malignant phenotype. Cancer Met. Rev. 1: 141–199.

    Article  CAS  Google Scholar 

  4. Ehrlich, P. 1906. Collected Studies on Immunity. Reprinted. 2: 442–447. Wiley, New York.

  5. Sikora, K. and Smedley, M. 1982. Clinical potential of monoclonal antibodies. Cancer Surveys 1: 521–542.

    Google Scholar 

  6. Trowbridge, I.S. and Domingo, D.L. 1982. Prospects for the clinical use of cytotoxic monoclonal antibody conjugates in the treatment of cancer. Cancer Surveys 1: 543–556.

    Google Scholar 

  7. Foon, K.A., Bernhard, M.I. and Oldham, R.K. 1982. Monoclonal antibody therapy: assessment by animal tumor models. J. Biol. Resp. Modifiers 1: 277–304.

    Google Scholar 

  8. Levy, R. and Miller, R.A. 1983. Tumor therapy with monoclonal antibodies. Fed. Proc. 42: 2650–2656.

    CAS  PubMed  Google Scholar 

  9. Arnon, R. and Sela, M. 1982. Targeted chemotherapy: drugs conjugated to anti-tumor antibodies. Cancer Surveys 1: 429–449.

    Google Scholar 

  10. Olsner, S. and Pihl, A. 1982. Cytotoxic proteins with intracellular site of action: mechanism of action and anti-cancer properties. Cancer Surveys 1: 467–487.

    Google Scholar 

  11. Gregoriadis, G., Senior, J., and Trouet, A. (eds.) 1982. Targeting of Drugs. Plenum, New York.

    Book  Google Scholar 

  12. Nicolau, C. and Poste, G. (eds.) 1983. Liposomes in vivo. Biol. Cell. (Special Issue) 47: 1–133.

    Google Scholar 

  13. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R. and Fidler, I.J. 1982. Analysis of the fate of systemically administered liposomes arid implications for their use in drug delivery. Cancer Res. 42: 1412–1422.

    CAS  PubMed  Google Scholar 

  14. Bruck, S.D. (ed.) 1982. Controlled Drug Delivery. CRC, Boca Raton.

    Google Scholar 

  15. Tomlinson, G. 1983. Unpublished data.

  16. Widder, K.J., Senyei, A.E. and Sears, B. 1982. Experimental methods in cancer therapeutics. J. Pharm. Sci. 71: 379–387.

    Article  CAS  Google Scholar 

  17. Poste, G. and Nicolson, G.L. 1983. Experimental systems for analysis of the surface properties of metastatic tumor cells, p. 341–364. In: Biomembranes. Volume II. A. Nowotny (ed.), Plenum, New York.

    Google Scholar 

  18. Baldwin, R.W. and Pimm, M.V. 1983. Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting. Cancer Met. Rev. 2: 89–106.

    Article  CAS  Google Scholar 

  19. Peterson, H.I. (ed.) 1979. Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors. CRC, Boca Raton.

    Google Scholar 

  20. Folkman, J. and Haudenschild, C. 1981. Induction of capillary growth in vitro, p. 119–136. In: J.T. Dingle and J.L. Gordon (eds.) Cellular-Interactions. Elsevier, Amsterdam.

    Google Scholar 

  21. Poste, G. 1983. Liposome targeting in vivo: Problems and opportunities. Biol. Cell. 47: 19–39.

    CAS  Google Scholar 

  22. Poste, G. 1983. Liposomes as a drug delivery system in cancer therapy. In: P. Sunkara (ed.), Novel Approaches to Cancer Chemotherapy. Academic, New York.

    Google Scholar 

  23. Parker, R.J., Sieber, S.M. and Weinstein, J.N. 1981. Effect of liposome encapsulation of a fluorescent dye on its uptake by the lymphatics of the rat. Pharmacology 23: 128–136.

    Article  CAS  Google Scholar 

  24. Mayhew, E., Rustum, Y.M. and Szoka, F. 1982. Therapeutic efficacy of cytosine arabinoside trapped in liposomes, p. 249–260. In: Targeting of Drugs. G. Gregoriadis, J. Senior, and A. Trouet (eds.), Plenum, New York.

    Chapter  Google Scholar 

  25. Hunt, C.A. 1982. Liposonres disposition in vivo. V. Liposome stability in plasma and implications for drug carrier function. Biochim. Biophys. Acta 719: 450–463.

    Article  CAS  Google Scholar 

  26. Profitt, R.T., Williams, L.E., Presant, C.A., Tin, G.W., Uliana, J.A., Gamble, R.C. and Baldeschwieler, J.D. 1983. Liposomal blockade of the reticuloendothelial system: Improved tumor imaging with small unilamellar vesicles. Science 220: 502–505.

    Article  Google Scholar 

  27. Dobson, E.L. and Jones, H.B. 1982. The behavior of intravenously injected particulate material. Its rate of disappearance from the blood stream as a measure of liver blood flow. Acta Med. Scand. 273 1–71.

    Google Scholar 

  28. Kato, T. 1982. Encapsulated drugs in targeted cancer therapy, p. 189–240. In: Controlled Drug Delivery, Vol. II. CRC, Boca Raton.

    Google Scholar 

  29. Greaves, M.F. 1982. “Target” structures and “target” cells for cancer therapy with monoclonal antibodies: finding the candidates. Cancer Surveys 1: 451–466.

    Google Scholar 

  30. Olsson, L. 1983. Phenotypic diversity in leukemia cell populations. Cancer Met. Rev. 2: 153–164.

    Article  CAS  Google Scholar 

  31. Webb, K.S., Ware, J.L., Parks, S.F., Briner, W.H., and Paulson, D.F. 1983. Monoclonal antibodies of different epitopes on a prostate tumor-associated antigen: Implications for immunotherapy. Cancer Immunol. Immunother. 14: 155–166.

    Article  CAS  Google Scholar 

  32. Machy, P., Barbet, J. and Leserman, L.D. 1982. Differential endocytosis of T and B lymphocyte surface molecules evaluated with anti body-bearing fluorescent liposomes containing methotrexate. Proc. Natl. Acad. Sci. USA 79: 4148–4152.

    Article  CAS  Google Scholar 

  33. Bragman, K.S., Heath, T.D. and Papahadjopoulos, D. 1983. Simultaneous interaction of monoclonal antibody-targeted liposomes with two receptors on K562 cells. Biochim. Biophys. Acta 730: 187–195.

    Article  CAS  Google Scholar 

  34. Marx, J.L. 1983. Suppressing autoimmunity in mice. Science 221: 843–845.

    CAS  Google Scholar 

  35. Lynch, W.E., Sartiano, G.P. and Ghaffar, A. 1980. Erythrocytes as carriers of chemotherapeutic agents for targeting to the reticuloendothelial system. Am. J. Hematol. 9: 249–259.

    Article  CAS  Google Scholar 

  36. Anghileri, L.J. (ed.) 1982. General Processes of Radiotracer Localization, Vols. I and II. CRC, Boca Raton.

    Google Scholar 

  37. Poste, G. and Fidler, I.J. 1982. Therapeutic amplification of macrophage-mediated destruction of tumor cells: an approach to cancer therapy that addresses the problem of tumor cell heterogeneity, p. 225–238. In: Design of Models for Testing Cancer Therapeutic Agents. I.J. Fidler and R.J. White (eds.), Van Nostrand, New York.

    Google Scholar 

  38. Fidler, I.J. and Poste, G. 1982. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin. Immunopathol. 5: 161–174.

    Article  CAS  Google Scholar 

  39. Lopez-Berestein, G., Mehta, R., Hopfer, R.L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M., Hersh, E.M. and Juliano, R. 1983. Treatment of prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J. Infec. Dis. 5: 939–945.

    Article  Google Scholar 

  40. Graybill, J.R., Craven, P.C., Taylor, R.L., Williams, D.M. and Magee, W.E. 1982. Treatment of murine cryptococcosis with liposome associated amphotericin B. J. Infect. Dis. 145: 748–751.

    Article  CAS  Google Scholar 

  41. Khato, J., Priester, E.R. and Sieber, S.M. 1982. Enhanced lymph node uptake of melphalan following liposomal entrapment and effects on lymph node metastasis in rats. Cancer Treatment Rep. 66: 517–527.

    CAS  Google Scholar 

  42. Hashida, M., Muranishi, S., Sezaki, S., Tanigawa, N., Satomura, K. and Hikasa, Y. 1979. Increased lymphatic delivery of bleomycin by microsphere in oil emulsion and its effect on lymph node metastasis. Int. J. Pharm. 2: 245–256.

    Article  CAS  Google Scholar 

  43. Weinstein, J.N., Parker, R.J., Keenan, A.M., Dower, S.K., Morse, H.C.III and Sieber, S.M. 1982. Monoclonal antibodies in the lymphatics: toward the diagnosis and therapy of tumor metastases. Science 218: 1334–1337.

    Article  CAS  Google Scholar 

  44. Mason, D.W., Thorpe, P.E. and Ross, W.C.J. 1982. Elimination of leukaemic cells from rodent bone marrow in vitro with antibody-ricin conjugates: implications for autologous marrow transplantation in man. Cancer Surveys 1: 389–416.

    Google Scholar 

  45. Muirhead, M., Martin, P.J., Torok-Storb, B., Uhr, J.W. and Vifetta, S. 1983. Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. Blood 62: 327–332.

    CAS  PubMed  Google Scholar 

  46. Federal Register 1983. Food and Drug Administration. Proposed new drug, antibiotic and biologic drug product regulations. 48: 26720–26749.

  47. Office of Biologics, Food and Drug Administration. 1983. Points to consider in the manufacture of in vitro monoclonal antibody products subject to licensure.

  48. Haber, E. 1983. Antibodies as models for rational drug design. Biochem. Pharmacol. 32: 1967–1977.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SmithKline & French Laboratories F30, 1500 Spring Garden Street, Philadelphia, PA, 19101

    George Poste & Richard Kirsh

  2. the Vice President for Research and Development of the SmithKline Beckman Corporation and Research Professor of Pathology and Laboratory Medicine at the University of Pennsylvania Medical School, Philadelphia

    George Poste

  3. a research scientist in the Department of Immunology at SmithKline Beckman,

    Richard Kirsh

Authors
  1. George Poste
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Kirsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poste, G., Kirsh, R. Site–Specific (Targeted) Drug Delivery in Cancer Therapy. Nat Biotechnol 1, 869–878 (1983). https://doi.org/10.1038/nbt1283-869

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1283-869

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing